Creating mouse models from patient tumors to study melanoma treatment resistance
Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core
This study is working to create special mouse models using tumor samples from melanoma patients to better understand why some treatments don’t work, with the hope of finding better ways to help people with melanoma respond to therapy.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10878839 on NIH RePORTER |
What this research studies
This research focuses on developing patient-derived xenograft (PDX) models and syngeneic mouse models to better understand the mechanisms of resistance to melanoma treatments. By collecting tumor biopsies from patients, the researchers aim to create a library of models that closely mimic the characteristics of individual tumors. This approach allows for more accurate testing of therapies and understanding of how tumors respond to treatment in a real-world context. The goal is to improve the effectiveness of existing therapies and develop new strategies to overcome resistance.
Who could benefit from this research
Good fit: Ideal candidates for participation are patients diagnosed with metastatic melanoma who are undergoing biopsy procedures.
Not a fit: Patients with non-melanoma skin cancers or those who are not undergoing biopsy procedures may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients by identifying and overcoming resistance mechanisms.
How similar studies have performed: Previous research using patient-derived xenograft models has shown promise in understanding cancer treatment responses, indicating that this approach is both tested and potentially impactful.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Moriceau, Gatien — University of California Los Angeles
- Study coordinator: Moriceau, Gatien
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.